Brought to you by 
Bausch initiates stalking horse bid process for Synergy Pharma; deal completed
01 Sep 2020
Executive Summary
Concurrent with filing for Chapter 11, Synergy Pharmaceuticals Inc. signed a definitive agreement under a court-supervised stalking horse bid process to sell substantially all its assets, including all rights to Trulance (plecanatide), to Bausch Health Companies Inc. for $200mm in cash
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bausch initiates stalking horse bid process for Synergy Pharma; deal completed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice